ReviewAmerican journal of clinical and experimental urology2014
Proinflammatory cytokine interleukin-6 in prostate carcinogenesis.
Review in American journal of clinical and experimental urology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 77 citations in OpenAlex.
- Article
- The heat of the battle: inflammation's role in prostate cancer development and inflammation-targeted therapies.Discover oncology · 2025Review
- Caffeic acid hinders the proliferation and migration through inhibition of IL-6 mediated JAK-STAT-3 signaling axis in human prostate cancer.Oncology research · 2024Article
- Melatonin and Prostate Cancer: Anti-tumor Roles and Therapeutic Application.Aging and disease · 2023Review
- Chemopreventive Activity of Ellagitannins fromPlants (Basel, Switzerland) · 2023Article
- Inflammation in Urological Malignancies: The Silent Killer.International journal of molecular sciences · 2023Review
- Ciliary Neurotrophic Factor Modulates Multiple Downstream Signaling Pathways in Prostate Cancer Inhibiting Cell Invasiveness.Cancers · 2022Article
- Influence of Systemic Therapy on the Expression and Activity of Selected STAT Proteins in Prostate Cancer Tissue.Life (Basel, Switzerland) · 2022Article
- The Correlation Between Platelet Count and Survival in Prostate Cancer.Research and reports in urology · 2022Article
- World Trade Center dust exposure promotes cancer in PTEN-deficient mouse prostates.Cancer research communications · 2022Article
- Impact of STAT Proteins in Tumor Progress and Therapy Resistance in Advanced and Metastasized Prostate Cancer.Cancers · 2021Review
- The Real Cytotoxic Effect of Artemisinins on Colon Cancer Cells in a Physiological Cell Culture Setting. How Composition of the Culture Medium Biases Experimental Findings.Pharmaceuticals (Basel, Switzerland) · 2021Article
- Association of Circulating Tumor Cells with Inflammatory and Biomarkers in the Blood of Patients with Metastatic Castration-Resistant Prostate Cancer.Life (Basel, Switzerland) · 2021Article
- Evaluation of cytokine expression and circulating immune cell subsets as potential parameters of acute radiation toxicity in prostate cancer patients.Scientific reports · 2020Article
- Review
- Cytokines and Chemokines as Mediators of Prostate Cancer Metastasis.International journal of molecular sciences · 2020Review
- Resistance to second generation antiandrogens in prostate cancer: pathways and mechanisms.Cancer drug resistance (Alhambra, Calif.) · 2020Review
- An organotin indomethacin derivative inhibits cancer cell proliferation and synergizes the antiproliferative effects of lapatinib in breast cancer cells.American journal of cancer research · 2020Article
- Article
- Identification of Potential miRNAs Biomarkers for High-Grade Prostate Cancer by Integrated Bioinformatics Analysis.Pathology oncology research : POR · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Interleukin-6 (IL-6) is a multifunctional pro-inflammatory cytokine which is expressed in clinical specimens obtained from patients with prostate cancer and in multiple cell lines. IL-6 expression is regulated in prostate cancer by several oncogenes and tumor suppressors. IL-6 activates in prostate cancer pathways of Janus kinases/signal transducers and activators of transcription (STAT), mitogen-activated protein kinases, and phosphatidylinositol 3-kinase. In several tumor models, proliferative and anti-apoptotic effects were described, although androgen-sensitive prostate cancer cells LNCaP are inhibited by IL-6. IL-6 is also involved in regulation of neuroendocrine differentiation and angiogenesis in prostate cancer. IL-6 activation of the androgen receptor is important for tumor growth and differentiation. IL-6 activation of STAT3 is crucial for maintenance of the tumor progenitor cells phenotype. Suppressors of cytokine signaling inhibit permanent activation of STAT3, however they may have also IL-6-independent effects. Experimental therapies with aim to inhibit IL-6 signaling in prostate cancer were developed with the monoclonal antibody CNTO328. Although progression towards castration resistance was delayed by CNTO328 in a xenograft model, clinical monotherapies in patients with castration therapy-resistant disease with the antibody did not yield a satisfactory response.
Indexed as
Identifiers
25374925PMC4219316W100143147What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.